Med2Date — Clinical Guidelines
Home Analgesia Analgesia in Cirrhosis

Analgesia in Cirrhosis

Last updated 1 Jun 2026 · Pain & analgesia

📋 Key Information Summary

📋
  • Paracetamol is first-line analgesia in cirrhosis — safe at ≤2 g/day in compensated disease and ≤2 g/day (with close monitoring) in decompensated disease; avoid exceeding recommended doses regardless of Child–Pugh class.
  • NSAIDs are contraindicated in all stages of cirrhosis due to the risk of hepatorenal syndrome, gastrointestinal haemorrhage, fluid retention, and worsening portal hypertension.
  • Opioid metabolism is profoundly altered in cirrhosis — reduced hepatic clearance, increased bioavailability (higher oral-to-IV ratio), and prolonged half-lives mandate dose reductions of 50% with extended intervals.
  • Child–Pugh and MELD scores guide analgesic choice — compensated (Child–Pugh A) patients tolerate a broader range of agents than decompensated (Child–Pugh B/C) patients.
  • Compensated cirrhosis (Child–Pugh A) permits cautious use of paracetamol at standard doses (≤4 g/day short-term), low-dose opioids, and select adjuvant agents with monitoring.
  • Decompensated cirrhosis (Child–Pugh B/C) requires strict dose reduction across all analgesic classes; paracetamol ≤2 g/day, opioids at 25–50% of standard dose, and avoidance of renally cleared agents if renal impairment coexists.
  • Avoid codeine and pethidine — codeine has unpredictable metabolism and accumulation of active metabolites; pethidine's metabolite norpethidine accumulates and causes seizures.
  • Tramadol is the preferred weak opioid but requires dose reduction (maximum 200 mg/day) and carries seizure risk; reduce dose further if eGFR <30 mL/min.
  • Gabapentinoids require caution — gabapentin and pregabalin are renally cleared and safer from a hepatic perspective, but dose adjustment is needed when renal impairment accompanies cirrhosis (hepatorenal syndrome).
  • Opioid-induced hepatic encephalopathy is a major risk — all opioids can precipitate or worsen encephalopathy; start low, monitor mental status, and discontinue if confusion develops.
  • Prioritise regional and non-pharmacological analgesia — nerve blocks, epidural analgesia (with coagulation correction), TENS, physiotherapy, and psychological strategies reduce systemic drug exposure.
  • Aboriginal and Torres Strait Islander Australians experience cirrhosis at significantly higher rates; culturally safe, accessible pain management and liaison with Aboriginal health workers is essential.

Introduction & Australian Epidemiology

Cirrhosis is the end-stage of chronic liver disease characterised by diffuse fibrosis, nodular regeneration, and progressive hepatic dysfunction. In Australia, liver disease is a leading cause of morbidity and mortality, with cirrhosis prevalence increasing over recent decades. The Australian Institute of Health and Welfare (AIHW) reports that liver disease accounted for over 7,400 deaths in 2021, with chronic liver disease and cirrhosis ranking among the top 20 causes of death nationally.

The management of pain in patients with cirrhosis poses a significant clinical challenge. Altered hepatic blood flow, impaired drug metabolism, reduced protein binding, portosystemic shunting, and coexisting renal dysfunction collectively change the pharmacokinetics and pharmacodynamics of virtually every analgesic class. Inappropriate analgesic prescribing is a common precipitant of hepatic decompensation, gastrointestinal bleeding, hepatorenal syndrome, and hepatic encephalopathy in this vulnerable population.

In Australia, the aetiology of cirrhosis is shifting. While hepatitis C-related cirrhosis is declining following the introduction of direct-acting antivirals (DAAs) on the PBS, alcohol-related liver disease (ARLD) and non-alcoholic steatohepatitis (NASH/MASLD) are rising. Aboriginal and Torres Strait Islander Australians bear a disproportionate burden, with liver disease mortality rates approximately three times higher than in the non-Indigenous population.

This guideline provides an evidence-based framework for analgesic prescribing in cirrhosis, stratified by disease severity (compensated vs. decompensated), with specific guidance on paracetamol, opioids, NSAIDs, adjuvant agents, and non-pharmacological strategies relevant to Australian practice.

⚠️
Clinical key point: Cirrhosis alters the pharmacokinetics of nearly all analgesics. The degree of hepatic impairment (Child–Pugh class) should be assessed before prescribing any analgesic agent. When in doubt, start at the lowest effective dose and titrate slowly with close monitoring.

Child–Pugh Classification

Parameter 1 Point 2 Points 3 Points
Bilirubin (µmol/L) <34 34–50 >50
Albumin (g/L) >35 28–35 <28
INR <1.7 1.7–2.3 >2.3
Ascites None Mild / controlled Moderate–severe
Encephalopathy None Grade I–II Grade III–IV

Interpretation: Class A (compensated) = 5–6 points; Class B = 7–9 points; Class C (decompensated) = 10–15 points.

Compensated Cirrhosis (Child–Pugh A)

Compensated cirrhosis (Child–Pugh score 5–6) represents a stage where hepatic synthetic function is relatively preserved, portal hypertension may be minimal or absent, and there is no ascites or encephalopathy. Patients may be asymptomatic or have non-specific symptoms. Drug metabolism is reduced but not profoundly impaired, and a broader range of analgesic options remains available.

Analgesic Strategy in Compensated Cirrhosis

1
First-line: Paracetamol
Up to 4 g/day for short-term use (≤5 days); 2–3 g/day for chronic use. Safe when used at recommended doses. Monitor LFTs if prolonged use.
2
Second-line: Low-dose tramadol
50 mg BD–TDS, maximum 200 mg/day. Preferred weak opioid. Monitor for nausea, constipation, and sedation.
3
Third-line: Low-dose strong opioid
Oxycodone 2.5–5 mg PRN (start 50% of standard dose) or morphine 2.5–5 mg PO/SC with extended intervals (q6–8h). Avoid codeine.
4
Adjuvants & non-pharmacological
Gabapentin/pregabalin for neuropathic pain; physiotherapy, TENS, psychological strategies. Regional nerve blocks where appropriate.
✅
Reassurance: Compensated cirrhosis patients can generally safely receive paracetamol at standard recommended doses for short courses. The outdated practice of blanket paracetamol avoidance in all liver disease is not evidence-based and may lead to inappropriate use of more harmful alternatives (e.g., NSAIDs or high-dose opioids).

Monitoring in Compensated Cirrhosis

  • Baseline LFTs, serum creatinine, eGFR, and coagulation studies before initiating regular analgesia.
  • Review LFTs after 2 weeks if on regular paracetamol or opioids.
  • Assess for early signs of decompensation: new-onset ascites, peripheral oedema, confusion, jaundice.
  • Document a clear analgesic plan with time-limited prescriptions and scheduled review dates.

Decompensated Cirrhosis (Child–Pugh B/C)

Decompensated cirrhosis (Child–Pugh score ≥7) is characterised by the development of clinically evident complications: ascites, variceal bleeding, hepatic encephalopathy, and jaundice. In this phase, hepatic drug metabolism is severely impaired, portosystemic shunting is significant, hypoalbuminaemia reduces drug protein binding (increasing free drug fractions), and hepatorenal syndrome may coexist. Analgesic prescribing becomes a high-risk activity requiring specialist input.

🚨
High-risk population: Decompensated cirrhosis patients have significantly increased risk of adverse drug reactions, including opioid-induced encephalopathy, NSAID-induced hepatorenal syndrome, and paracetamol toxicity at lower absolute doses. Always involve the treating hepatologist or gastroenterologist in analgesic planning for inpatients. For community-managed patients, consult the local liver service or use state-based hepatology telehealth.

Analgesic Strategy in Decompensated Cirrhosis

Child–Pugh B (7–9)
Moderate Impairment
Paracetamol ≤2 g/day. Opioids at 50% standard dose with extended intervals. Tramadol preferred. Avoid codeine, pethidine, NSAIDs. Consider gabapentinoids with renal dose adjustment.
Setting: GP with hepatology co-management or specialist clinic
Child–Pugh C (10–15)
Severe Impairment
Paracetamol ≤2 g/day with close monitoring. Opioids at 25–50% standard dose, PRN only, with daily review. Strongly prefer regional analgesia and non-pharmacological methods. Involve pain medicine specialist and hepatologist.
Setting: Inpatient with hepatology and pain service input

Key Pharmacokinetic Changes in Decompensated Cirrhosis

Change Mechanism Clinical Effect
Reduced hepatic extraction Decreased hepatocyte mass and portal blood flow Increased oral bioavailability of high-extraction drugs (morphine, oxycodone, tramadol)
Hypoalbuminaemia Reduced hepatic synthesis Increased free (active) fraction of protein-bound drugs (NSAIDs, diazepam)
Portosystemic shunting Portal hypertension → collateral circulation Drugs bypass first-pass metabolism; CNS drug delivery increases
Impaired Phase I metabolism CYP450 enzyme downregulation Prolonged half-lives of CYP-metabolised drugs (codeine, tramadol, oxycodone)
Renal impairment (hepatorenal) Functional renal failure from splanchnic vasodilation Accumulation of renally cleared metabolites (morphine-6-glucuronide, gabapentin, pregabalin)
Coagulopathy Reduced synthesis of clotting factors + thrombocytopenia Increased bleeding risk with NSAIDs, regional procedures require correction

Practical Approach for Acute Pain in Decompensated Cirrhosis (Inpatient)

  1. Assess severity and cause of pain — exclude surgical abdomen, spontaneous bacterial peritonitis (SBP), and hepatocellular carcinoma (HCC) before attributing pain to known chronic conditions.
  2. Check coagulation (INR, platelets) and correct if regional or procedural analgesia is planned (FFP, platelets, vitamin K as per local transfusion protocol).
  3. Start paracetamol 1 g QID (max 4 g/day) for acute short-term use (≤48 h) if Child–Pugh B; ≤2 g/day if Child–Pugh C or hepatorenal syndrome present.
  4. If additional analgesia required: morphine SC 1–2.5 mg q4–6h PRN or oxycodone liquid 1.25–2.5 mg PO q4–6h PRN. Titrate slowly with 4-hourly neurological observations.
  5. Avoid patient-controlled analgesia (PCA) unless supervised by an acute pain service with hepatology input — high risk of over-sedation and encephalopathy.
  6. Review daily: Mental status (West Haven criteria for encephalopathy), respiratory rate, renal function, fluid balance.

Paracetamol in Cirrhosis

Paracetamol (acetaminophen) remains the recommended first-line analgesic in cirrhosis when used at appropriate doses. Despite longstanding clinical dogma suggesting it is dangerous in liver disease, evidence demonstrates that paracetamol at therapeutic doses is safe and is significantly less harmful than NSAIDs or high-dose opioids in this population.

ℹ️
Evidence update: A systematic review by Chandok and Watt (2016) confirmed that paracetamol ≤4 g/day does not cause hepatotoxicity in chronic liver disease. The 2019 American College of Gastroenterology (ACG) guidelines recommend paracetamol as the safest analgesic in cirrhosis, with dose reduction only in advanced (decompensated) disease or malnutrition.
💊
Paracetamol
Panadol®, Panamax®, Dymadon® · Non-opioid analgesic
Adult dose — Compensated 500 mg–1 g PO/PR QID (max 4 g/day short-term; 2–3 g/day chronic)
Adult dose — Decompensated 500 mg PO TDS–QID (max 2 g/day)
Paediatric dose 15 mg/kg PO/PR q4–6h (max 60 mg/kg/day); dose adjustment not required for compensated cirrhosis
Route Oral, rectal, IV (Perfalgan®)
Renal adjustment Extend interval to q6h if eGFR <30 mL/min; max 2 g/day if on dialysis
Hepatic adjustment Child–Pugh A: standard dose short-term; Child–Pugh B/C: max 2 g/day; avoid in acute liver failure
PBS status ✔ PBS General Benefit

Paracetamol Dosing Guide by Hepatic Impairment

Cirrhosis Stage Max Daily Dose Duration Monitoring
Child–Pugh A (compensated) 4 g/day short-term; 2–3 g/day chronic Short courses preferred; review at 2 weeks LFTs at baseline and 2 weeks if regular use
Child–Pugh B (moderate) 2–3 g/day As short as possible; review weekly LFTs, creatinine, INR at baseline and weekly
Child–Pugh C (severe) ≤2 g/day Acute use only; daily clinical review Daily LFTs, creatinine, INR, clinical assessment
Acute liver failure AVOID N/A N/A
Malnourished / low body weight (<50 kg) ≤2 g/day regardless of Child–Pugh Short courses only LFTs at baseline and 1 week
⚠️
Hidden paracetamol sources: Always check for concurrent paracetamol-containing combination preparations (e.g., co-codamol, Panadeine Forte®, cold and flu tablets). Patients may inadvertently exceed safe doses through multiple products. Counsel patients to read labels and maintain a medication list.

NSAIDs — Contraindicated in Cirrhosis

🚫
NSAIDs are contraindicated in ALL stages of cirrhosis. This includes both non-selective NSAIDs (ibuprofen, naproxen, diclofenac, indomethacin) and COX-2 selective inhibitors (celecoxib). This is a strong recommendation supported by Therapeutic Guidelines (eTG), the Royal Australasian College of Physicians, and international hepatology societies.

NSAIDs are among the most dangerous drug classes in cirrhosis. Their use is associated with a constellation of potentially fatal complications that arise from the interplay between prostaglandin inhibition and the haemodynamic derangements of portal hypertension.

Why NSAIDs Are Dangerous in Cirrhosis

Complication Mechanism Clinical Significance
Hepatorenal syndrome NSAIDs inhibit renal prostaglandins that maintain renal perfusion in the setting of reduced effective arterial blood volume Can precipitate acute kidney injury progressing to hepatorenal syndrome type 1 — a life-threatening complication
GI haemorrhage Gastric mucosal prostaglandin depletion + impaired platelet function + portal hypertensive gastropathy Variceal and non-variceal upper GI bleeding risk markedly increased; associated with higher mortality in cirrhotic patients
Fluid retention & ascites Sodium and water retention via prostaglandin inhibition at the renal tubule Worsens ascites, peripheral oedema, and dilutional hyponatraemia; may necessitate large-volume paracentesis
Worsening portal hypertension Increased intrahepatic vascular resistance from reduced vasodilatory prostaglandins Elevated portal pressure increases variceal bleeding risk
Hypoalbuminaemia amplification Reduced protein binding → higher free drug fraction → enhanced toxicity at standard doses Even a single dose of an NSAID may cause significant adverse effects in severe cirrhosis

Commonly Encountered NSAIDs to Avoid

Drug Australian Brands Notes
Ibuprofen Nurofen®, Brufen® Available OTC — patients may self-medicate; counsel proactively
Naproxen Naprosys®, Inza® Long half-life; prolonged risk window
Diclofenac Voltaren® Also hepatotoxic; double risk in liver disease
Celecoxib Celebrex® COX-2 selective but still contraindicated — retains renal prostaglandin effects
Meloxicam Mobic® Partial COX-2 selectivity; not safer in cirrhosis
Piroxicam Feldene® Very long half-life (50 h); extreme accumulation risk
⚠️
Patient counselling essential: All patients with cirrhosis should be advised to avoid over-the-counter NSAIDs (particularly ibuprofen from pharmacies and supermarkets). Medication allergy lists and My Health Record entries should document NSAID contraindication. Consider a Medication Management Review (MBS Item 900) for complex cases.

Topical NSAIDs — A Nuanced Position

Topical NSAIDs (e.g., diclofenac gel [Voltaren Emulgel®]) have significantly lower systemic absorption than oral formulations. While they are not formally contraindicated, they should be used with caution and only for localised musculoskeletal pain when no alternative exists. Avoid application to large areas or broken skin. Systemic absorption increases with prolonged use over large body surface areas.

Opioid Use in Cirrhosis

Opioids are frequently required for moderate-to-severe pain in cirrhosis but carry substantial risks including respiratory depression, constipation (worsening hepatic encephalopathy via increased ammonia absorption), oversedation, and precipitation of encephalopathy. The choice of opioid, dose, and route must be tailored to the degree of hepatic impairment.

💊
Tramadol
Tramal® · Weak opioid / SNRI
Adult dose — Compensated 50 mg PO BD–TDS (max 200 mg/day)
Adult dose — Decompensated 50 mg PO BD (max 100 mg/day); use with extreme caution
Renal adjustment eGFR 10–30: max 100 mg/day; eGFR <10: max 50 mg/day or avoid
Hepatic adjustment Child–Pugh A: 50% dose reduction; Child–Pugh B/C: avoid if possible
PBS status ✔ PBS General Benefit
💊
Morphine
MS Contin®, Kapanol®, Ordine® · Strong opioid
Adult dose — Compensated 2.5–5 mg PO q6–8h PRN; or 1–2.5 mg SC q4–6h PRN
Adult dose — Decompensated 1–2.5 mg PO q8–12h PRN; or 0.5–1 mg SC q6h PRN. Avoid if eGFR <30
Key concern Active metabolite morphine-6-glucuronide accumulates in renal impairment — prolonged sedation and respiratory depression
Hepatic adjustment Reduce dose 50% in Child–Pugh A; reduce 75% in B/C; avoid sustained-release formulations
PBS status ⚠ PBS Authority Required
💊
Oxycodone
Endone®, OxyNorm® · Strong opioid
Adult dose — Compensated 2.5–5 mg PO q4–6h PRN
Adult dose — Decompensated 1.25–2.5 mg PO q6–8h PRN; immediate-release only
Key concern CYP3A4 and CYP2D6 metabolism impaired; avoid sustained-release formulations in decompensated disease
PBS status ⚠ PBS Authority Required
💊
Fentanyl (transdermal)
Durogesic® · Strong opioid
Adult dose — Compensated 12 µg/h patch q72h (only if opioid-tolerant and stable dose)
Adult dose — Decompensated Generally AVOID — unpredictable absorption with oedema and altered skin perfusion
Key concern Hepatic metabolism (CYP3A4) but no active metabolites; absorption erratic in oedematous patients
PBS status ⛔ PBS Authority Required (Specialist)

Opioids to AVOID in Cirrhosis

🚫
  • Codeine — Unpredictable CYP2D6 metabolism produces variable morphine levels; risk of toxicity in poor metabolisers and overdose risk in ultra-rapid metabolisers. Not recommended in any stage of cirrhosis.
  • Pethidine (meperidine) — Metabolite norpethidine accumulates with repeated dosing and causes seizures; half-life is markedly prolonged in hepatic impairment. Contraindicated in cirrhosis.
  • Dextropropoxyphene — Withdrawn in many countries; hepatotoxic metabolite; cardiac toxicity risk. Not available on current PBS but may be encountered in legacy prescriptions.

Opioid Monitoring Protocol

  • Respiratory rate, sedation score (e.g., Pasero Opioid-Induced Sedation Scale), and pain assessment every 4 hours in inpatients.
  • Daily assessment for hepatic encephalopathy using the West Haven criteria (mental status, asterixis, number connection test).
  • Monitor bowel function — constipation worsens hyperammonaemia; prescribe stool softeners (e.g., lactulose 15–30 mL BD) prophylactically.
  • Renal function (creatinine, eGFR) every 48–72 hours or with any clinical deterioration.
  • Avoid concurrent benzodiazepines, antihistamines, and other CNS depressants — additive sedation risk.

Adjuvant & Non-Pharmacological Analgesia

Non-opioid adjuvant analgesics and non-pharmacological strategies are critically important in cirrhosis as they reduce reliance on systemic drugs with hepatic metabolism. These should be considered at every stage of the WHO analgesic ladder in cirrhotic patients.

Adjuvant Agents

💊
Gabapentin
Neurontin® · Anticonvulsant / neuropathic pain
Adult dose Start 100 mg nocte, titrate to 100–300 mg TDS as tolerated
Renal adjustment eGFR 30–59: max 300 mg BD; eGFR 15–29: max 300 mg OD; eGFR <15: 100–200 mg OD or avoid
Hepatic adjustment Not hepatically metabolised — safe in cirrhosis if renal function normal; adjust for hepatorenal syndrome
PBS status ⚠ PBS Authority Required
💊
Pregabalin
Lyrica® · Anticonvulsant / neuropathic pain
Adult dose Start 25–75 mg BD, titrate to 150 mg BD (max 300 mg BD)
Renal adjustment eGFR 30–59: 25–75 mg BD; eGFR 15–29: 25–50 mg OD–BD; eGFR <15: 25 mg OD
Hepatic adjustment Minimal hepatic metabolism — dose adjustment not required for hepatic impairment alone
PBS status ⚠ PBS Authority Required
💊
Amitriptyline
Endep® · Tricyclic antidepressant / neuropathic pain
Adult dose Start 10 mg nocte, titrate to 25–75 mg nocte
Key concern CYP2D6/CYP2C19 metabolism; anticholinergic effects may precipitate constipation and encephalopathy. Use with extreme caution in decompensated cirrhosis. Consider nortriptyline as slightly less anticholinergic alternative.
PBS status ✔ PBS General Benefit

Non-Pharmacological Strategies

  • Regional nerve blocks: Intercostal, transversus abdominis plane (TAP), and ilioinguinal blocks can provide excellent analgesia for abdominal wall and post-procedural pain with minimal systemic effects. Coordinate with hepatology for coagulation correction (INR <1.5, platelets >50 × 10⁹/L) prior to needle procedures.
  • Epidural analgesia: Effective for post-surgical pain (e.g., hepatic resection, TIPS) but requires coagulation correction. Discuss with anaesthetist and hepatologist.
  • Transcutaneous electrical nerve stimulation (TENS): Non-invasive, no drug interactions, suitable for musculoskeletal and neuropathic pain.
  • Physiotherapy and exercise: Graded activity programs for chronic musculoskeletal pain. Avoid excessive bed rest which worsens sarcopenia (common in cirrhosis).
  • Cognitive-behavioural therapy (CBT) and mindfulness: Address the psychosocial dimensions of chronic pain; particularly important as patients with cirrhosis have high rates of anxiety and depression.
  • Heat/cold therapy, acupuncture: Low-risk adjuncts. Ensure acupuncture needles are inserted carefully given coagulopathy risk.

Monitoring & Safety Framework

All patients with cirrhosis receiving analgesic therapy require a structured monitoring plan tailored to disease severity and the agents prescribed.

Recommended Monitoring Schedule

Parameter Compensated (CP-A) Decompensated (CP-B/C)
LFTs (ALT, AST, GGT, ALP, bilirubin) Baseline, then 2-weekly if on regular analgesia Baseline, then weekly or with any clinical change
INR / Coagulation Baseline Baseline and at least weekly
Serum creatinine / eGFR Baseline, then 2-weekly Baseline, then 2–3 times/week inpatient; weekly outpatient
Serum albumin Baseline Baseline and at least fortnightly
Mental status / encephalopathy Clinical assessment at each visit Daily (inpatient) using West Haven criteria; include number connection test
Fluid balance / ascites Assess at each visit Daily weights, strict fluid balance inpatient
Pain assessment (NRS/VAS) At each consultation 4-hourly inpatient; scheduled review in clinic
Bowel function Assess at each visit (opioid constipation risk) Daily stool chart; prophylactic lactulose if on opioids
⚠️
Red flags — seek urgent hepatology/medical review: New-onset confusion or agitation (possible encephalopathy), rising creatinine (hepatorenal syndrome), haematemesis or melaena (GI bleeding), increasing ascites or peripheral oedema, jaundice deepening, or rising INR after commencing analgesia.

Special Populations

🤰 Pregnancy
Paracetamol: First-line in pregnancy — safe at recommended doses. No dose adjustment needed unless cirrhosis is decompensated (then use ≤2 g/day).
NSAIDs: Contraindicated in pregnancy (particularly ≥30 weeks gestation due to premature ductus arteriosus closure) AND cirrhosis — dual contraindication.
Opioids: Use lowest effective dose for shortest duration. Neonatal abstinence syndrome risk with prolonged use. Codeine is contraindicated (unpredictable metabolism in both pregnancy and cirrhosis).
Involve obstetric medicine and hepatology early for joint management planning.
👶 Paediatrics
Paracetamol: 15 mg/kg PO/PR q4–6h (max 60 mg/kg/day). Reduce maximum dose in paediatric liver disease — use 50% of standard max if significant hepatic impairment.
Ibuprofen: 5–10 mg/kg PO TDS — CONTRAINDICATED if child has cirrhosis; use paracetamol alone or with specialist pain input.
Opioids: Morphine 0.1–0.2 mg/kg PO q4h or 0.05–0.1 mg/kg SC q4h. Start at lower end; monitor closely. Avoid codeine (TGA advisory: contraindicated in children <12 years, and contraindicated in ultra-rapid CYP2D6 metabolisers at any age).
Paediatric hepatology and pain service involvement strongly recommended.
👴 Elderly
General: Age-related decline in hepatic blood flow (20–30% reduction by age 70) compounds cirrhosis-related changes. Lower starting doses for all analgesics.
Paracetamol: Maximum 2–3 g/day in elderly cirrhosis patients regardless of Child–Pugh class.
Opioids: Start at 50% of the already-reduced cirrhosis dose. Monitor for falls, confusion, and urinary retention. Avoid long-acting formulations.
Anticholinergic burden: Avoid TCAs (amitriptyline, doxepin) — increased confusion and falls risk; consider gabapentin or pregabalin instead.
Complete a comprehensive geriatric medication review (MBS Item 900). Consider Home Medicines Review.
🫘 Renal Impairment
Hepatorenal syndrome: A medical emergency — do not use NSAIDs under any circumstances. Morphine and codeine are contraindicated (active metabolites accumulate). Fentanyl is relatively safer (no active metabolites) but requires dose reduction.
Gabapentinoids: Require renal dose adjustment — gabapentin and pregabalin accumulate with declining eGFR. Use lowest effective dose and titrate very slowly.
Paracetamol: Safe in renal impairment at standard doses; reduce to ≤2 g/day if on dialysis.
Always calculate eGFR in cirrhotic patients — serum creatinine may be deceptively low due to reduced muscle mass (sarcopenia). Cystatin C-based eGFR may be more accurate.
🫀 Hepatic Impairment
This entire guideline addresses hepatic impairment. Refer to the Compensated and Decompensated Cirrhosis sections for stratified recommendations.
Acute-on-chronic liver failure (ACLF): A separate entity with very high mortality — all analgesics should be reviewed and minimised by the hepatology team. ICU-level monitoring may be required.
For patients listed for liver transplant, coordinate analgesic planning with the transplant anaesthesia team pre-operatively.
🛡️ Immunocompromised
Post-transplant patients: Liver transplant recipients on immunosuppression (tacrolimus, cyclosporine) may have drug interactions with analgesics. Tacrolimus levels may be affected by CYP3A4 inhibitors. Avoid NSAIDs long-term due to calcineurin inhibitor nephrotoxicity.
HIV co-infection: Antiretroviral drug interactions with opioids (particularly protease inhibitors and CYP3A4). Consult the HIV pharmacist or use an interaction checker (e.g., Liverpool HIV Interactions).
Immunosuppressed patients should avoid NSAIDs due to increased infection risk and GI mucosal vulnerability.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Australians experience liver disease at rates three to five times higher than the non-Indigenous population, with hepatitis B, hepatitis C, alcohol-related liver disease, and non-alcoholic fatty liver disease (NAFLD/MASLD) all contributing to a disproportionate burden of cirrhosis. The AIHW reports that liver disease is a leading contributor to the health gap between Indigenous and non-Indigenous Australians.

Pain management in this population must be delivered in a culturally safe, trauma-informed, and strengths-based manner. Many Aboriginal and Torres Strait Islander patients with cirrhosis live in rural and remote communities with limited access to specialist hepatology and pain medicine services.

Geographic access
Specialist hepatology and pain medicine services are concentrated in metropolitan centres. Patients in remote NT, WA, and QLD communities may need aeromedical retrieval or telehealth consultation. Use the Royal Flying Doctor Service (RFDS) and state-based liver telehealth programs (e.g., NT Liver Service, WA Liver Wellness).
Medication access
Remote Aboriginal Community Controlled Health Organisations (ACCHOs) may have limited PBS formulary options. Ensure Essential Medicines List includes paracetamol, tramadol, and gabapentin. Coordinate with Remote Area Aboriginal Health Practitioners for medication supply continuity through CARPA Standard Treatment Manual.
Cultural safety
Use culturally appropriate pain assessment tools. Recognise that pain expression varies across cultures; some patients may underreport pain. Ask about pain using open-ended, non-judgemental language. Involve Aboriginal Health Workers (AHWs) and Aboriginal Liaison Officers (ALOs) in care planning. Respect sorry business, kinship obligations, and connection to country when planning care.
Stigma and trust
Patients may avoid healthcare due to past negative experiences, institutional racism, or fear of being labelled "drug-seeking." Build rapport through continuity of care with trusted providers. Avoid stigmatising language about alcohol or substance use. Provide non-judgemental, patient-centred care.
Health literacy
Provide medication information in plain English and, where available, in local Aboriginal languages. Use visual aids and pictorial medication charts. Aboriginal Health Workers are essential for health education about NSAID avoidance, safe paracetamol dosing, and when to seek help for worsening liver symptoms.
Polypharmacy and comorbidity
Aboriginal and Torres Strait Islander Australians with cirrhosis frequently have concurrent diabetes, chronic kidney disease, cardiovascular disease, and rheumatic heart disease. Complex polypharmacy increases adverse drug event risk. Regular medication reviews (MBS Item 900 or equivalent through ACCHO) are recommended.
ℹ️
Key resources: RHDAustralia (www.rhdaustralia.com.au) provides culturally appropriate clinical resources for rheumatic heart disease and related conditions in Aboriginal and Torres Strait Islander communities. NACCHO member ACCHOs provide integrated, holistic primary care. The CARPA Standard Treatment Manual (8th edition) guides remote prescribing in the Northern Territory and beyond.

Quick Reference: Analgesic Selection by Cirrhosis Stage

Stage
First-line
Second-line
Avoid
Child–Pugh A (Compensated)
Paracetamol ≤4 g/day (short-term); ≤3 g/day (chronic)
Tramadol 50 mg BD–TDS; gabapentin/pregabalin
NSAIDs, codeine, pethidine
Child–Pugh B (Moderate)
Paracetamol ≤2–3 g/day
Tramadol 50 mg BD; low-dose morphine PRN
NSAIDs, codeine, pethidine, sustained-release opioids
Child–Pugh C (Severe)
Paracetamol ≤2 g/day
Morphine SC 0.5–1 mg PRN; regional blocks; non-pharmacological
All NSAIDs, codeine, pethidine, TCAs, sustained-release opioids, PCA without pain service

📚 References

  1. 1. Chandok N, Watt KDS. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc. 2010;85(5):451–458. doi:10.4065/mcp.2009.0534
  2. 2. Lee A, Aneeza BH. Paracetamol use in chronic liver disease. Am J Ther. 2016;23(6):e1825–e1831. doi:10.1097/MJT.0000000000000408
  3. 3. European Association for the Study of the Liver (EASL). Clinical Practice Guideline: Drug-induced liver injury. J Hepatol. 2019;70(6):1222–1261. doi:10.1016/j.jhep.2019.02.014
  4. 4. Sola E, Gines P. Challenges and management of liver cirrhosis: practical issues in the therapy of patients with cirrhosis. J Hepatol. 2022;76(6):1339–1352. doi:10.1016/j.jhep.2021.12.026
  5. 5. Australian Institute of Health and Welfare (AIHW). Liver and biliary cancers in Australia. Cat. no. CAN 128. Canberra: AIHW; 2023.
  6. 6. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806–815. doi:10.1038/clpt.2011.58
  7. 7. Rogal S, Hansen L, Patel A, et al. AASLD Practice Guidance: Palliative care and symptom management for patients with cirrhosis. Hepatology. 2022;75(5):1272–1294. doi:10.1002/hep.32378
  8. 8. National Aboriginal Community Controlled Health Organisation (NACCHO). National Guide to a Preventive Health Assessment for Aboriginal and Torres Strait Islander People. 3rd ed. Melbourne: RACGP/NACCHO; 2018.
  9. 9. CARPA Reference Group. Central Australian Rural Practitioners Association Standard Treatment Manual. 8th ed. Alice Springs: CARPA; 2022.
  10. 10. Drugs and Therapeutics Advisory Committee, Northern Territory Department of Health. NT Medicines Formulary. Darwin: NT Government; 2024.
  11. 11. Abraldes JG, Albillos A, Bañares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136(5):1651–1658. doi:10.1053/j.gastro.2009.01.043
  12. 12. Terg R, Casciato P, Garbe C, et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study. J Hepatol. 2015;62(5):1056–1060. doi:10.1016/j.jhep.2014.12.010
for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.
Preventive health
Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction
Paracetamol ± NSAID; manual therapy
2–6 weeks
Provocable on palpation; no red flags
Thoracic compression fracture
Paracetamol; ± calcitonin; DXA + osteoporosis Rx
6–12 weeks healing
Elderly; osteoporosis; acute onset
ACS (posterior MI)
Aspirin 300 mg, GTN, heparin; urgent PCI
Time-critical
ECG, troponin; CV risk factors
Aortic dissection
IV labetalol; urgent CT aortogram; surgery (Type A)
Time-critical
Tearing pain; BP differential >20 mmHg
Vertebral osteomyelitis
IV antibiotics (vancomycin + ceftriaxone initially); ID consult
6 weeks IV antibiotics
Fever, elevated CRP, IV drug use
Biliary colic / cholecystitis
Paracetamol ± morphine; lap cholecystectomy
Surgical within 72 h (cholecystitis)
RUQ/infrascapular; post-prandial; RUQ US

📚 References

  1. 1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
  2. 2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
  3. 3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
  4. 4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760–765.
  5. 5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60–75.
  6. 6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395–403.
  7. 7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
  8. 8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581–E593.
  9. 9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112–120.
  10. 10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144–153.
  11. 11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
  12. 12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805–811.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).